Contraindicated in:
Use Cautiously in:
Derm: rash, pruritus, urticaria.
GI: CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), abdominal pain, diarrhea, nausea, vomiting.
Hemat: bleeding, blood dyscrasias, hemolytic anemia.
Local: pain at IM site, phlebitis at IV site.
Neuro: encephalopathy, SEIZURES (HIGH DOSES IN PATIENTS WITH RENAL IMPAIRMENT).
Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS) , superinfection.
Drug-Drug:
(Generic available)
Renal Impairment
Fortaz, Tazicef
Spectrum:
Therapeutic Classification: anti-infectives
Pharmacologic Classification: third generation cephalosporins
Absorption: Well absorbed following IM administration; IV administration results in complete bioavailability.
Distribution: Widely distributed. Crosses the placenta; enters breast milk in low concentrations. CSF penetration better than with first- and second-generation agents.
Protein Binding: 17%.
Metabolism/Excretion: 8090% excreted unchanged in urine.
Half-life: Neonates: 2.24.7 hr; Adults: 2 hr (↑ in renal impairment).
NDC Code*